Tin tức & Cập nhật
Xem bài viết Da liễu
Xem
Chỉ hiển thị Multimedia

Immune-related AEs predict survival in cancer patients on ICI
05 May 2023
Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.
05 May 2023

Tralokinumab a promising treatment option in young people with moderate-to-severe AD
29 Apr 2023
Targeting interleukin (IL)-13 with tralokinumab monotherapy helps reduce disease activity in adolescents with moderate-to-severe atopic dermatitis (AD) with a low frequency of conjunctivitis throughout the treatment period, according to data from the phase III ECZTRA 6 trial.
29 Apr 2023






